Literature DB >> 2184040

Acute haemodynamic and neurohumoral effects of intravenous nisoldipine in patients with severe congestive heart failure.

H H Erlemeier1, W Kupper, W Bleifeld.   

Abstract

Twenty patients (5 females, 15 males) with severe heart failure (NYHA IV), due to coronary artery disease in 14, and congestive cardiomyopathy in 6, received an intravenous bolus of the calcium blocker nisoldipine 0.2 mg followed by a continuous infusion of 0.2 micrograms.kg-1.min-1. Haemodynamic measurements were performed at baseline and after 30 min. The mean arterial pressure fell from 91 to 73 mmHg, pulmonary capillary wedge pressure from 31 to 26 mm Hg and systemic vascular resistance from 1695 to 1040 dyn.s.cm-5. The cardiac index (2.2 to 2.71.min-1.m-2, and stroke volume index (25 to 33 ml.m-2) were markedly increased. There was no reflex tachycardia as the heart rate dropped from 92 to 85 beats.min-1. Plasma renin activity and norepinephrine concentration did not change significantly. The findings indicate that nisoldipine acts as a strong vasodilator and that it has a beneficial acute haemodynamic effect in patients with severe left heart failure irrespective of its aetiology.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184040     DOI: 10.1007/bf00314795

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Is nisoldipine capable of reducing left ventricular preload?

Authors:  P D Verdouw; C J Slager; R H Van Bremen; C M Verkeste
Journal:  Eur J Pharmacol       Date:  1984-02-10       Impact factor: 4.432

2.  Salutary hemodynamic and sustained clinical beneficial effects of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure.

Authors:  A Kimchi; A G Ellrodt; Y Charuzi; W Shell; G H Murata
Journal:  Am Heart J       Date:  1985-08       Impact factor: 4.749

3.  Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist.

Authors:  D C Warltier; C M Meils; G J Gross; H L Brooks
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

4.  Effects of verapamil on [3H]norepinephrine release.

Authors:  T T Zsotér; C Wolchinsky; L Endrenyi
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

5.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

6.  Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.

Authors:  J N Barjon; J L Rouleau; D Bichet; C Juneau; J De Champlain
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

7.  Hemodynamic effects of nisoldipine in chronic congestive heart failure.

Authors:  A Vogt; H Kreuzer
Journal:  Arzneimittelforschung       Date:  1983

8.  [Comparison of the acute hemodynamic effect of nisoldipine (Bay k 5552) and nifedipine in patients with ischemia-induced left ventricular impaired function].

Authors:  W Aschenberg; C Nienaber; R Spielmann; W Bleifeld
Journal:  Z Kardiol       Date:  1988-04

9.  Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris.

Authors:  U Thadani; S F Hamilton; E Olson; J L Anderson; R Prasad; W Voyles; R Doyle; E Kirsten; S M Teague
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

10.  Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure.

Authors:  U Elkayam; A Roth; W Hsueh; L Weber; L Freidenberger; S H Rahimtoola
Journal:  Am Heart J       Date:  1986-06       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.